The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy

Alessandro Rambaldi, Cristina Boschini, Giuseppe Gritti, Federica Delaini, Elena Oldani, Andrea Rossi, Anna Maria Barbui, Daniele Caracciolo, Marco Ladetto, Angela Gueli, Alberto De Crescenzo, Roberto Passera, Liliana Devizzi, Caterina Patti, Alessandro Massimo Gianni, Corrado Tarella

Research output: Contribution to journalArticlepeer-review

Abstract

The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B-cell lymphoma (DLBCL). We reviewed the outcome of 1,057 DLBCL patients followed from 1984 to 2012 at four centers. LMR was analyzed as a clinical biomarker by receiver-operating characteristic (ROC) analysis and Harrell's C-statistics. Patients were characterized by a median age of 61 years, International Prognostic Index (IPI) score of >2 in 39%, and were treated with a rituximab-containing chemotherapy in 66%. LMR proved strongly predictive for survival in patients treated with rituximab-based programs, but not in those receiving chemotherapy alone. Additionally, an LMR value of ≤2.6 (as determined by ROC analysis) was associated with a worst performance status, a higher lactate dehydrogenase (LDH) level, an advanced clinical stage, and a higher IPI score (P=0.000). In patients treated with rituximab-supplemented chemotherapy programs, an LMR value of

Original languageEnglish
Pages (from-to)1062-1067
Number of pages6
JournalAmerican Journal of Hematology
Volume88
Issue number12
DOIs
Publication statusPublished - Dec 2013

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy'. Together they form a unique fingerprint.

Cite this